{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:59:04Z","timestamp":1790225944613,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.chest.2026.07.5242","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T07:03:37Z","timestamp":1787209417000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mepolizumab and Dupilumab Show No Significant Difference in Reducing Exacerbations in Patients With COPD and an Eosinophilic Phenotype"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7649-038X","authenticated-orcid":false,"given":"Jean","family":"Bourbeau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Kolterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Hunger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank C.","family":"Sciurba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chest.2026.07.5242_bib1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejim.2024.10.015","article-title":"Chronic obstructive pulmonary disease's eosinophilic phenotype: Clinical characteristics, biomarkers and biotherapy","volume":"131","author":"Maniscalco","year":"2025","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.chest.2026.07.5242_bib2","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2147\/COPD.S194367","article-title":"Exacerbations and health care resource use among patients with COPD in relation to blood eosinophil counts","volume":"14","author":"M\u00fcllerov\u00e1","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"9","key":"10.1016\/j.chest.2026.07.5242_bib3","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1164\/rccm.201509-1869OC","article-title":"Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The Copenhagen General Population Study","volume":"193","author":"Vedel-Krogh","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.chest.2026.07.5242_bib4","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.jaip.2017.10.004","article-title":"Relationship of blood eosinophil count to exacerbations in chronic obstructive pulmonary disease","volume":"6","author":"Zeiger","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"10.1016\/j.chest.2026.07.5242_bib5","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1111\/all.14297","article-title":"Human airway epithelial cells express a functional IL-5 receptor","volume":"75","author":"Barretto","year":"2020","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.chest.2026.07.5242_bib6","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jaci.2021.05.043","article-title":"Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease","volume":"148","author":"Buchheit","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.chest.2026.07.5242_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nri3341","article-title":"Eosinophils: changing perspectives in health and disease","volume":"13","author":"Rosenberg","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.chest.2026.07.5242_bib8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3389\/fmed.2017.00093","article-title":"The biology of eosinophils and their role in asthma","volume":"4","author":"McBrien","year":"2017","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.chest.2026.07.5242_bib9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1164\/rccm.202201-0209PP","article-title":"Blood eosinophils and chronic obstructive pulmonary disease: a Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 review","volume":"206","author":"Singh","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.chest.2026.07.5242_bib10","doi-asserted-by":"crossref","first-page":"00576","DOI":"10.1183\/23120541.00576-2021","article-title":"Type 2 inflammation in asthma and other airway diseases","volume":"8","author":"Maspero","year":"2022","journal-title":"ERJ Open Res"},{"issue":"2","key":"10.1016\/j.chest.2026.07.5242_bib11","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/thoraxjnl-2020-215167","article-title":"Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait","volume":"76","author":"David","year":"2021","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.chest.2026.07.5242_bib12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s41030-024-00280-0","article-title":"Eosinophilic chronic obstructive pulmonary disease. What do we know so far?","volume":"11","author":"Bartziokas","year":"2025","journal-title":"Pulm Ther"},{"key":"10.1016\/j.chest.2026.07.5242_bib13","series-title":"Nucala (mepolizumab): highlights of prescribing information","year":"2025"},{"issue":"17","key":"10.1016\/j.chest.2026.07.5242_bib17","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.chest.2026.07.5242_bib18","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1056\/NEJMoa2413181","article-title":"Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype","volume":"392","author":"Sciurba","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.chest.2026.07.5242_bib19","series-title":"Dupixent (dupilumab): highlights of prescribing information","year":"2024"},{"issue":"3","key":"10.1016\/j.chest.2026.07.5242_bib20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2303951","article-title":"Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts","volume":"389","author":"Bhatt","year":"2023","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.chest.2026.07.5242_bib21","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1056\/NEJMoa2401304","article-title":"Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation","volume":"390","author":"Bhatt","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.chest.2026.07.5242_bib22","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S2213-2600(24)00409-0","article-title":"Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials","volume":"13","author":"Bhatt","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"26","key":"10.1016\/j.chest.2026.07.5242_bib23","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1056\/NEJMe1806037","article-title":"New biologics for asthma","volume":"378","author":"Drazen","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.chest.2026.07.5242_bib26","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","article-title":"Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research","volume":"15","author":"Signorovitch","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.chest.2026.07.5242_bib27","series-title":"Global strategy for prevention, diagnosis and management of COPD: 2025 report","year":"2025"},{"issue":"2","key":"10.1016\/j.chest.2026.07.5242_bib28","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1378\/chest.06-0702","article-title":"Development and validation of an improved, COPD-specific version of the St. George Respiratory Questionnaire","volume":"132","author":"Meguro","year":"2007","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.chest.2026.07.5242_bib29","first-page":"576","article-title":"Interpreting evaluating respiratory symptoms(TM) in COPD diary scores in clinical trials: terminology, methods, and recommendations","volume":"9","author":"Leidy","year":"2022","journal-title":"Chronic Obstr Pulm Dis"},{"key":"10.1016\/j.chest.2026.07.5242_bib30","series-title":"St George\u2019s Respiratory Questionnaire for COPD patients (SGRQ-C): manual (version 1.4)","author":"Jones","year":"2023"},{"issue":"10","key":"10.1016\/j.chest.2026.07.5242_bib31","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","article-title":"Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept","volume":"28","author":"Signorovitch","year":"2010","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"10.1016\/j.chest.2026.07.5242_bib32","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.chest.2026.07.5242_bib33","article-title":"Dupilumab versus mepolizumab for COPD: evaluating efficacy outcomes using placebo-adjusted indirect treatment comparison","author":"Bhatt","year":"2025","journal-title":"Pulm Ther"},{"issue":"17","key":"10.1016\/j.chest.2026.07.5242_bib34","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1056\/NEJMe2503292","article-title":"Mepolizumab in COPD\u2014if at first you don't succeed","volume":"392","author":"Dransfield","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.chest.2026.07.5242_bib35","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1056\/NEJMe2305752","article-title":"Biologics for COPD\u2014finally here","volume":"389","author":"Agusti","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.chest.2026.07.5242_bib36","series-title":"Global strategy for prevention, diagnosis and management of COPD: 2026 report","year":"2026"},{"key":"10.1016\/j.chest.2026.07.5242_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2025.108343","article-title":"Efficacy of dupilumab and mepolizumab in eosinophilic COPD: insights from phase 3 trials","volume":"248","author":"Suter","year":"2025","journal-title":"Respir Med"},{"key":"10.1016\/j.chest.2026.07.5242_bib38","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.2147\/COPD.S294333","article-title":"Mepolizumab for eosinophil-associated COPD: analysis of METREX and METREO","volume":"16","author":"Pavord","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.chest.2026.07.5242_bib39","doi-asserted-by":"crossref","unstructured":"Bafadhel M, Criner GJ, Min J, Kolterer S, Mayer B, Papi A. Mepolizumab efficacy is durable up to 104 weeks in patients with chronic obstructive pulmonary disease: results from the MATINEE phase III randomized controlled trial. Paper presented at: American Thoracic Society 2025 International Conference (P1380); 2025; San Francisco, CA.","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A1307"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369226064366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369226064366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:59:33Z","timestamp":1790222373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369226064366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":34,"alternative-id":["S0012369226064366"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2026.07.5242","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mepolizumab and Dupilumab Show No Significant Difference in Reducing Exacerbations in Patients With COPD and an Eosinophilic Phenotype","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2026.07.5242","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}]}}